ChromaVision Launches Four Automated Tests for More Accurate Assessment of Cancer.Business Editors and Health/Medical Writers SAN JUAN CAPISTRANO San Juan Capistrano (săn wän kăpĭsträ`nō), city (1990 pop. 26,183), Orange co., S Calif.; inc. 1961. San Juan Capistrano has some manufactures, including aircraft parts, medical apparatus, and boats, but the economy is , Calif.--(BUSINESS WIRE)--Feb. 1, 2000 ChromaVision Medical Systems Inc. (Nasdaq:CVSN), developer of unique cellular imaging diagnostics and manufacturer of the Automated Cellular Imaging System (ACIS)(TM), Tuesday announced that it has released four new ACIS applications that will allow cancer physicians to more accurately predict how a particular patient's cancer will act, and thereby more effectively tailor therapy for each patient. The four tests are estrogen receptor estrogen receptor A protein of a superfamily of nuclear receptors for small hydrophilic ligands–eg, steroid hormones, thyroid hormone, vitamin D, retinoids; the presence of ERs in breast CA generally is associated with a better prognosis, as they respond to (ER), progesterone receptor progesterone receptor A progesterone-binding protein complex found in the cytoplasm of certain cells in particular of the breast, which belongs to the nuclear receptor family. See Progesterone receptor assay. Cf Estrogen receptor. (PR), p53 protein expression and Ki-67 cell proliferation marker. These prognostic prog·nos·tic adj. 1. Of, relating to, or useful in prognosis. 2. Of or relating to prediction; predictive. n. 1. A sign or symptom indicating the future course of a disease. 2. and predictive markers, in addition to the HER2 protein expression test, released in September of 1999 for use with the ACIS, are among the most common tools used by physicians to determine the potential aggressiveness of individual cancer tumors. The availability of these tests using ACIS allows for a significant improvement in accuracy, objectivity and efficiency when assessing critical characteristics of cancer at the cellular level. For example, in breast cancer, when assessing the percentage of cells in a tumor that are positive for a given marker, researchers using the ACIS are ten times more precise than when reading slides manually. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the American Cancer Society American Cancer Society, n.pr established in 1913, this national volunteer-based health organization is committed to the elimination of cancer through prevention and treatment and to diminishing cancer suffering through advocacy, scholarship, research, , approximately 180,000 women will be diagnosed with breast cancer in 2000, and the vast majority of these women will undergo one or more of these tests at initial diagnosis and during the treatment process. According to Michael F. Press, M.D., Ph.D., a leading cancer researcher at the Kenneth Norris, Jr. Comprehensive Cancer Center at the University of Southern California The U.S. News & World Report ranked USC 27th among all universities in the United States in its 2008 ranking of "America's Best Colleges", also designating it as one of the "most selective universities" for admitting 8,634 of the almost 34,000 who applied for freshman admission , &uot;The availability of these new ACIS tests enables the pathologist to provide a more objective and reproducible analysis of tumor characteristics. As a pathologist, this will allow me to be more certain when classifying patients for treatment, as well as to determine what kind of response can be expected from a patient to a particular treatment.&uot; ChromaVision President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Douglas S. Harrington, M.D., commented, &uot;The release of the balance of tests that constitute the full tumor panel is a clear benefit to patients, who will receive better care, and pathologists, who can more accurately characterize tumors and guide therapy. It is also a significant milestone in the ChromaVision commercialization effort as it adds four high-value tests to our growing diagnostic menu. The ACIS platform now supports six tests and more are expected to be launched in 2000.&uot; Each of these tissue-based tests is based upon the immunohistochemical staining method that was cleared for use with the ACIS by the U.S. Food and Drug Administration in July 1999. Other ACIS tests that are now available for clinical use include HER2/neu for breast cancer and micrometastases detection in bone marrow, an emerging technique to evaluate and stage many types of cancer. About ChromaVision Medical Systems ChromaVision Medical Systems manufactures and markets an advanced cellular imaging system designed to advance the detection, diagnosis and treatment of cellular disease. The Automated Cellular Imaging System (ACIS)(TM) combines proprietary, color-based imaging technology with automated microscopy to bring unprecedented sensitivity, accuracy and reproducibility to cancer, infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. and genetic cell-based diagnostics. ChromaVision currently markets its products to physicians and researchers in university medical centers and commercial laboratories throughout the world. ChromaVision Medical Systems Inc. (Nasdaq:CVSN) was formed by XL Vision Inc., and is a Safeguard Scientifics Inc. (NYSE NYSE See: New York Stock Exchange :SFE See Sydney Futures Exchange. ) partnership company. For more information on ChromaVision Medical Systems Inc., visit the company's Web site at http://www.chromavision.com. The statements contained herein regarding ChromaVision Medical Systems Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to, uncertainty of success in developing any new diagnostic test, failure to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance or approval for particular applications and dependence on third parties for clinical testing. ACIS is a Trademark of ChromaVision Medical Systems Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion